Neurocrine Biosciences Reports P-III Study (CAHtalyst) Results of Crinecerfont for Congenital Adrenal Hyperplasia in Adults
- The P-III study evaluated the efficacy, safety, and tolerability of crinecerfont in 182 adult patients aged ≥18yrs. with CAH due to 21-hydroxylase deficiency (21-OHD)
- The study met its 1EPs at 24wk. & showed that patients treated with crinecerfont achieved a significant percent reduction in daily glucocorticoid (GC) dose over PBO while maintaining androgen control. The study also met its 2EPs & showed a reduction in androstenedione at 4wk.
- Patients achieved a reduction to a physiologic GC dose (63% vs 18%) at 24wk. & was generally well tolerated. Additionally, the P-III pediatric study (CAHtalyst) results are expected to be available in early Q4’23
Ref: PRNewswire | Image: Neurocrine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.